Obstructive Sleep Apnea in Inflammatory Arthritis: Disease-Specific Evidence and Clinical Implications
Journal of Clinical Medicine · 13.11.2026 · 15 (22) · 8904
DOI: 10.3390/jcm15228904 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.11.2026. Verfasst von Claudiu Avram und 5 weiteren Autor:innen. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Victor Babeș” University of Medicine and Pharmacy, Timișoara, Romania.
Abstract (Originalsprache)
Background/Objectives: Obstructive sleep apnea (OSA) may complicate fatigue and cardiovascular risk assessment in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). We evaluate the strength and clinical applicability of disease-specific evidence.
Methods
This expert narrative review uses a documented PubMed/MEDLINE update through 28 October 2026, supplemented by reference-list checking, general OSA trials, and professional guidance. Evidence is appraised qualitatively by ascertainment, selection, adjustment, and directness.
Results
RA has the largest but most heterogeneous evidence base: pooled OSA prevalence was 29.8% (95% confidence interval [CI], 15.2–46.7%; I2 = 99.6%), with mixed definitions. In PsA, 21/42 polysomnography (PSG)-tested volunteers had OSA (50%; descriptive 95% CI, 35.5–64.5%), whereas 22/247 clinic patients had a recorded diagnosis (8.9%; 95% CI, 6.0–13.1%). These estimates are not interchangeable. Ankylosing spondylitis (AS) findings differ between matched objective testing and administrative cohorts. Adiposity, demographics, medication, and surveillance constrain interpretation. Positive airway pressure has established sleep-related indications; improvements in arthritis activity or arthritis-specific cardiovascular events remain unproven. Tirzepatide evidence concerns adults with obesity and moderate-to-severe OSA.
Conclusions
PsA and axSpA evidence remains limited. Shared biology supports a conceptual hypothesis rather than a demonstrated causal axis. Targeted case finding should lead to guideline-concordant objective diagnosis; universal asymptomatic rheumatology screening and disease-modifying effects of OSA treatment are not established.
Förderung
- “Victor Babeș” University of Medicine and Pharmacy, Timișoara, Romania
Zitieren
APA
Avram, C., Craciun, M., Pah, A., Isacov, I., Duse, A. O., & Avram, C. A. (2026). Obstructive Sleep Apnea in Inflammatory Arthritis: Disease-Specific Evidence and Clinical Implications. Journal of Clinical Medicine, 15(22), 8904. https://doi.org/10.3390/jcm15228904
Vancouver
Avram C, Craciun M, Pah A, Isacov I, Duse AO, Avram CA. Obstructive Sleep Apnea in Inflammatory Arthritis: Disease-Specific Evidence and Clinical Implications. Journal of Clinical Medicine. 2026;15(22):8904. doi:10.3390/jcm15228904
BibTeX
@article{Avram2026,
author = {Avram, Claudiu and Craciun, Maria-Laura and Pah, Ana-Maria and Isacov, Iasmina and Duse, Adina Octavia and Avram, Cristiana Adina},
title = {Obstructive Sleep Apnea in Inflammatory Arthritis: Disease-Specific Evidence and Clinical Implications},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {22},
pages = {8904},
doi = {10.3390/jcm15228904}
}
EUVIMED